Merck & Co Inc

NYSE:MRK   3:59:58 PM EDT
110.19
+1.35 (+1.24%)
4:04:15 PM EDT: $110.12 -0.07 (-0.06%)
Products, Litigation

U.S. Court Of Appeals For The Federal Circuit Rules In Favor Of Merck In Sitagliptin Dihydrogen Phosphate Patent Lawsuit

Published: 09/29/2022 19:30 GMT
Merck & Co Inc (MRK) - U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit.
Merck & Co Inc - Ruling From U.S. Court of Appeals Provides Januvia, Janumet and Janumet Xr Patent Protection Through May 2027.
Merck & Co Inc - Ruling From U.S. Court of Appeals Provides Januvia, Janumet and Janumet Xr Six Months of Pediatric Exclusivity.